Safety of Non-steroidal Anti-inflammatory Drugs as Part of Enhanced Recovery After Laparoscopic Sleeve Gastrectomy—A Systematic Review and Meta-Analysis

[11] Angadi SS(2018)Effect of laparoscopic sleeve gastrectomy vs laparoscopic roux-en-y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial Jama. 319 255-893

[12] Ciftci B(2022)Bariatric surgery with Roux-En-Y gastric bypass or sleeve gastrectomy for treatment of obesity and comorbidities: current evidence and practice Cureus. 14 e25762-4576

[13] Ekinci M(2019)Safety and efficacy of non-steroidal anti-inflammatory drugs (nsaids) used for analgesia after bariatric surgery: a retrospective case-control study Obes Surg. 29 911-111

[14] Celik EC(2021)Impact of non-steroidal anti-inflammatory drugs on the efficiency of enhanced recovery programmes after colorectal surgery: a retrospective study of the GRACE database Anaesth Crit Care Pain Med. 40 100880-416

[15] Ng JJ(2020)Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations Gut. 69 617-188

[16] Leong WQ(2020)Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective Biochem Pharmacol. 180 114147-323

[17] Tan CS(2015)Symptomatic marginal ulcer disease after Roux-en-Y gastric bypass: incidence, risk factors and management Obes Surg. 25 805-11

[18] Cottam D(2022)Nonsteroid anti-inflammatory drugs and the risk of peptic ulcers after gastric bypass and sleeve gastrectomy Surg Obes Relat Dis. 18 888-391

[19] Qureshi FG(2021)Oral drug dosing following bariatric surgery: general concepts and specific dosing advice Br J Clin Pharmacol. 87 4560-401

[20] Mattar SG(2011)The pathophysiology of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in stomach and small intestine J Clin Biochem Nutr. 48 107-3279

[11] Angadi SS(2018)Effect of laparoscopic sleeve gastrectomy vs laparoscopic roux-en-y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial Jama. 319 255-893

[12] Ciftci B(2022)Bariatric surgery with Roux-En-Y gastric bypass or sleeve gastrectomy for treatment of obesity and comorbidities: current evidence and practice Cureus. 14 e25762-4576

[13] Ekinci M(2019)Safety and efficacy of non-steroidal anti-inflammatory drugs (nsaids) used for analgesia after bariatric surgery: a retrospective case-control study Obes Surg. 29 911-111

[14] Celik EC(2021)Impact of non-steroidal anti-inflammatory drugs on the efficiency of enhanced recovery programmes after colorectal surgery: a retrospective study of the GRACE database Anaesth Crit Care Pain Med. 40 100880-416

[15] Ng JJ(2020)Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations Gut. 69 617-188

[16] Leong WQ(2020)Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective Biochem Pharmacol. 180 114147-323

[17] Tan CS(2015)Symptomatic marginal ulcer disease after Roux-en-Y gastric bypass: incidence, risk factors and management Obes Surg. 25 805-11

[18] Cottam D(2022)Nonsteroid anti-inflammatory drugs and the risk of peptic ulcers after gastric bypass and sleeve gastrectomy Surg Obes Relat Dis. 18 888-391

[19] Qureshi FG(2021)Oral drug dosing following bariatric surgery: general concepts and specific dosing advice Br J Clin Pharmacol. 87 4560-401

[20] Mattar SG(2011)The pathophysiology of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in stomach and small intestine J Clin Biochem Nutr. 48 107-3279